Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

By sjmartinez • July 20, 2024

Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM; ACTIV-2/A5401 Study Team. Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. J Infect Dis. 2024 Jul 20:jiae369. doi: 10.1093/infdis/jiae369. Epub ahead of print. PMID: 39028902.

Tags: ACTIV-2, casirivimab/imdevimab, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, outpatient treatment, polyclonal antibodies, Publications, SAB-185, transchromosomic

Related Posts

Cardiovascular Risks and Outcomes Among Chinese American Immigrants: Insights From the Multi-Ethnic Study of Atherosclerosis

Cai X, White Q, Wang DR, DeFilippi CR, Bertoni AG, Wu CO, Liu K, Lima JAC, Budoff MJ, Fonarow GC, Watson KE, McClelland RL, Yang[...]

Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Volpe G, Jurkute N, Girafa G, Zimmermann HG, Motamedi S, Bereuter C, Pandit L, D'Cunha A, Yeaman MR, Smith TJ, Cook LJ, Brandt AU, Paul[...]

Single-cell detection of copy number changes reveals dynamic mechanisms of adaptation to antifungals in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Beach A, Soisangwan N, Billings CL, Burrack LS, Filler SG, Selmecki A. Single-cell detection of copy number[...]